Business description: Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Number of employees: 8

Sales by Activity: Seelos Therapeutics, Inc.

Fiscal Period: December 2019 (USD) 2020 (USD) 2021 (USD) 2022 (USD) 2023 (USD)

Pharmaceuticals

375K - - - 2.2M

Geographical breakdown of sales: Seelos Therapeutics, Inc.

Fiscal Period: December 2019 (USD) 2020 (USD) 2021 (USD) 2022 (USD) 2023 (USD)

United States

375K - - - 2.2M

Executive Committee: Seelos Therapeutics, Inc.

Manager TitleAgeSince
Chief Executive Officer 66 2018-12-31
Investor Relations Contact - 2018-12-31

Company details: Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc.

300 Park Avenue

10022, New York

+

http://www.seelostherapeutics.com
address Seelos Therapeutics, Inc.(SEELQ)

Bio Therapeutic Drugs

Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1
-1.34%-3.09%+56.10%+68.83% 65.45B
-0.86%-3.86%+6.90%+89.13% 58.93B
+0.63%+0.75%+26.70%+87.85% 55.21B
-2.34%-3.90%+10.90%+115.97% 46.1B
+0.09%-6.08%+18.67%+25.90% 42.49B
-2.58%+0.24%+18.54%+41.28% 35.56B
-1.76%-11.56%+126.44%+649.27% 34.57B
+0.17%-0.54%+77.41%+58.15% 32.46B
-1.69%-0.79%-40.58%+382.68% 26.28B
Average -0.96%-3.06%+33.45%+168.78% 40B
Weighted average by Cap. -1.00%-3.29%+33.56%+143.33%
  1. Stock Market
  2. Stocks
  3. SEELQ Stock
  4. Company Seelos Therapeutics, Inc.